Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Bremelanotide

Demonstrates the difference between an authorised peptide product and unvalidated nasal or multi agent formulations marketed around the same ingredient.

Conceptual three-dimensional molecular signature for Bremelanotide; not an exact chemical structure.
Melanocortin receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved for a specific US product and indication

MHRA / UK LICENCE

No equivalent UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access identified

PRIVATE LAWFUL USE CONTEXT

Not a routine licensed UK wellness treatment; research presentations are distinct from Vyleesi

EVIDENCE MATURITY

Controlled evidence for a specific labelled US use

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Moderate research market

PROFESSIONAL RELEVANCE

Separate the US labelled product from PT-141 research presentations and observed combinations.

Product, formulation and indication

Vyleesi

US · Autoinjector

Acquired generalised HSDD in premenopausal women

Status history

Production baseline verification recorded.

FDA approved as Vyleesi for a defined indication

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.